These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38849845)

  • 21. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
    Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM
    Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
    Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
    Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a
    Conci N; Marchiori V; Federico AD; Giglio A; Sperandi F; Melotti B; Gelsomino F
    Per Med; 2024; 21(4):205-209. PubMed ID: 38958204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
    Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
    Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion-Positive High-Grade Glioma.
    Simoneau J; Robertson P; Muraszko K; Maher CO; Garton H; Calvert R; Koschmann C; Upadhyaya SA; Mody R; Brown N; Kumar-Sinha C; Parmar H; Camelo-Piragua S; Franson AT
    J Natl Compr Canc Netw; 2024 Sep; 22(7):. PubMed ID: 39236755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity.
    van den Heuvel CNAM; Navis AC; de Bitter T; Amiri H; Verrijp K; Heerschap A; Rex K; Dussault I; Caenepeel S; Coxon A; Span PN; Wesseling P; Hendriks W; Leenders WPJ
    Mol Cancer Res; 2017 Nov; 15(11):1587-1597. PubMed ID: 28751462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
    Xu B; Muramatsu T; Inazawa J
    Mol Cancer Res; 2021 Apr; 19(4):585-597. PubMed ID: 33443139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
    Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
    Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
    Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
    [No Abstract]   [Full Text] [Related]  

  • 34. Infantile fibrosarcoma-like tumor driven by novel
    Gupta A; Belsky JA; Schieffer KM; Leraas K; Varga E; McGrath SD; Koo SC; Magrini V; Wilson RK; White P; Mardis ER; Jatana KR; Cottrell CE; Setty BA
    Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
    Bao ZS; Chen HM; Yang MY; Zhang CB; Yu K; Ye WL; Hu BQ; Yan W; Zhang W; Akers J; Ramakrishnan V; Li J; Carter B; Liu YW; Hu HM; Wang Z; Li MY; Yao K; Qiu XG; Kang CS; You YP; Fan XL; Song WS; Li RQ; Su XD; Chen CC; Jiang T
    Genome Res; 2014 Nov; 24(11):1765-73. PubMed ID: 25135958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
    Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
    EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
    Zhang L; Scorsone K; Woodfield SE; Zage PE
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.